ArriVent BioPharma, Inc. Common Stock
AVBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $32,167 | $27,720 | $61,289 | $20,163 |
| G&A Expenses | $6,149 | $5,903 | $5,483 | $3,542 |
| SG&A Expenses | $6,149 | $5,903 | $5,483 | $3,542 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $38,316 | $33,623 | $66,772 | $23,705 |
| Operating Income | -$38,316 | -$33,623 | -$66,772 | -$23,705 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,338 | $2,224 | $2,385 | $3,072 |
| Pre-Tax Income | -$34,978 | -$31,399 | -$64,387 | -$20,633 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$34,978 | -$31,399 | -$64,387 | -$20,633 |
| % Margin | – | – | – | – |
| EPS | -0.83 | -0.9 | -1.9 | -0.61 |
| % Growth | 7.8% | 52.6% | -211.5% | – |
| EPS Diluted | -0.83 | -0.9 | -1.9 | -0.61 |
| Weighted Avg Shares Out | 41,913 | 35,006 | 33,899 | 33,582 |
| Weighted Avg Shares Out Dil | 41,913 | 35,006 | 33,899 | 33,582 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,338 | $2,224 | $2,385 | $3,072 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$34,978 | -$31,399 | -$66,772 | -$23,705 |
| % Margin | – | – | – | – |